The isothermal nucleic acid amplification technology market is expected to grow at a CAGR of 9.2% during the forecast period. The growth of the market is attributed the growing funding initiatives for molecular diagnostics & infectious diseases, and recent launches of INAAT consumables by prominent market players. However, the unfavorable reimbursement scenario for in vitro diagnostic tests is a major factor restraining market growth.
The report Isothermal Nucleic Acid Amplification
Technology Market is projected to reach USD 6.8 billion by 2028 from
USD 4.4 billion in 2023, at a CAGR of 9.2% during the forecast period.
KEY MARKET DYNAMICS
1
DRIVERS
1 Recent launches of INAAT consumables by prominent market players
2 Growing funding initiatives for molecular diagnostics & infectious
disease diagnostics
3 High prevalence of infectious diseases
2
RESTRAINTS
1 Unfavorable reimbursement scenario for in vitro diagnostic tests
3
OPPORTUNITIES
1 INAAT tests as point-of-care tools
2 Start-ups focusing on INAAT
4
CHALLENGES
1
Dominance of PCR
Download
PDF Brochure: - https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=839
Market Segmentation
·
Based on the product, the INAAT market is
segmented into assay, kits, and reagents, and systems. The assay, kits, and
reagents segment accounted for the largest share in 2022.
·
Based on technology, the isothermal nucleic acid
amplification technology market is segmented into loop-mediated isothermal
amplification (LAMP), transcription-mediated amplification (TMA), strand
displacement amplification (SDA), nicking enzyme amplification reaction (NEAR),
single-primer isothermal amplification (SPIA), and other technologies.
·
Based on application, the INAAT market is segmented
into infectious disease diagnosis, blood screening, and other applications. The
disease diagnosis segment is expected to dominate the market in 2022.
·
Based on the end user, the market is divided into
hospitals, reference laboratories, academic and research institutes, and other
end users. The hospital segment is expected to account for the largest share of
the INAAT market in 2022.
Regional Analysis
North America is expected to account for the largest share of
the global INAAT market, followed by Europe in 2022. The largest share of the
North American market is attributed to the presence of a leading market
players, growing burden of infectious diseases and availability of R&D
funding for molecular diagnostics.
Request
for Sample Pages: - https://www.marketsandmarkets.com/requestsampleNew.asp?id=839
Recent Developments
·
In May 2022, Hologic, Inc. (US) received CE marking
for two new molecular assays, Panther Fusion EBV Quant Assay and Panther Fusion
BKV Quant Assay, expanding its transplant pathogen monitoring menu on the
Panther Fusion system.
·
In December 2021, Hologic, Inc. (US) launched
Panther Trax, which offers full automation to meet high-volume testing demands
and will be commercially available in the US, Europe, Canada, Australia, and
New Zealand.
·
In September 2020, Abbott (US) received approval
from Health Canada for the ID NOW rapid COVID-19 testing device for use in
Canada.
Top Key Players
The prominent players operating in INAAT market are Grifols,
S.A. (Spain), Hologic, Inc. (US), Abbott Laboratories (US), Becton, Dickinson
and Company (US), Meridian Bioscience (US), Eiken Chemical Co., Ltd. (Japan),
bioMérieux SA (France), Tecan Trading AG (Switzerland), New England Biolabs
(US), QIAGEN N.V. (Germany), DiaSorin S.p.A. (Italy), General Electric (US),
OptiGene Limited (UK), Quidel Corporation (US), Thermo Fisher Scientific (US),
Genomtec (Poland), Mast Group Ltd. (UK), Ustar Biotechnologies (China), Jena
Bioscience GmbH (Germany), Atila BioSystems (US), TwistDx Limited (UK), LGC
Limited (UK), Life Sciences Advanced Technologies (US), GenoSensor Corporation
(US), and PCR Biosystems (UK).
No comments:
Post a Comment